of the renin-angiotensin-aldosterone system. These findings suggest that the effect of NE on vasoconstricBackground. In non-diabetic subjects, an attenuated systemic norepinephrine (NE ) responsiveness may tion is not counteracted effectively by ACE inhibition treatment alone. contribute to the mechanisms of action of angiotensinconverting enzyme (ACE) inhibitor treatment. We Key words: angiotensin-converting enzyme inhibition; determined whether ACE inhibitor treatment influinsulin-dependent diabetes mellitus; norepinephrine ences systemic and renal haemodynamic responsiveness responsiveness; renal and systemic haemodynamics to exogenous NE, as well as urinary albumin excretion during NE, in microalbuminuric insulin-dependent diabetic (IDDM ) patients, representing a patient category that benefits by strict blood pressure control.
Introduction
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(10 mg/day), given at 08.00 a.m. The same NE doses were NE responsiveness [14, 15] , but this has not been administered during this second evaluation. The patients also studied in IDDM complicated by microalbuminuria. participated in another study that aimed to compare the It is of particular relevance to evaluate the NE renal haemodynamic and microproteinuric NE responses in responsiveness after ACE inhibition treatment in mic-micro-and normoalbuminuric IDDM patients and control roalbuminuric IDDM patients, because control of fac-subjects, and the pre-enalapril data were also used for that tors that contribute to a blood pressure rise in such study [13] . One initially studied patient declined to patients appears to be indicated to prevent progression participate in the second evaluation. to overt nephropathy.
The experiments were carried out in a temperatureThe purpose of our study was, therefore, to evaluate controlled room kept at 22°C. The subjects were studied after an overnight fast and remained fasting during the the effect of enalapril treatment on systemic and renal experiments. Smoking was prohibited and no liquid to drink, haemodynamic responsiveness to exogenous NE in other than water, was allowed. The subjects remained in the IDDM patients with microalbuminuria.
supine position and were only allowed to stand on voiding. Two hours before the start of the renal haemodynamic measurements, each subject drank 600 ml of water to pro-
Subjects and methods
mote diuresis. Thereafter, urinary volume losses were replaced by water drinking. An euglycaemic insulin clamp Subjects was used to minimize the effects of differences in actual glycaemia on renal hemodynamics [16 ] and to avoid changes The study was approved by the local medical ethics in insulin levels during the experiments potentially influencing committee, and all participants gave written informed con-NE sensitivity. Insulin was infused ( Velosulin H.M., Novosent. The patients were considered insulin-dependent, and Nordisk, Bagsvaerd, Denmark) at a rate of 30 mU/kg/h. glucagon-stimulated C-peptide levels were <0.2 nmol/l. Blood glucose was kept at 5 mmol/l by varying the infusion Seven patients (six men, one woman) participated. They had rate of a 20% glucose solution. Potassium chloride (10 mmol a mean age of 48±9 (mean±SD) years and a diabetes per 100 g of glucose) was added to the glucose vials. duration of 29±5 years. None had severe obesity (body Glomerular filtration rate (GFR) and effective renal mass index ranging from 23.5 to 27.9 kg/m2). All of the plasma flow ( ERPF ) were measured simultaneously using patients had persistent microalbuminuria [defined as a urin-primed infusions of [125I ]iothalamate and [131I ]hippurate, ary albumin excretion rate ( Ualb.V ) between 20 and respectively [16 ] . The clearances were calculated using the 200 mg/min in at least two out of three overnight urine formulae U.V/P and I.V/P, respectively. U.V represents the collections for a 1 year period ]. All patients were treated urinary excretion rate of the tracer, I.V represents the infusion with enalapril for elevated blood pressure related to the rate of the tracer, and P represents the tracer value of plasma presence of incipient nephropathy (systolic/diastolic blood samples taken at the end of each clearance period. Errors in pressure >140/90 mmHg), but none had essential hyperten-the estimation of GFR due to incomplete bladder emptying sion before development of microalbuminuria. ACE inhibi-and dead space were corrected by multiplying the clearance tion treatment was stopped for 6 weeks before the start of of [125I ]iothalamate by the formula: clearance of the study. Without enalapril, six patients had a systolic blood [131I ]hippurate (I.V/P)/clearance of [131I ]hippurate ( U.V/P). pressure >140 mmHg and one patient had a diastolic blood The coefficients of variation for GFR and ERPF are 2.2 and pressure >90 mmHg. None of the patients had untreated 5.0%, respectively [16 ] . The GFR and ERPF were corrected proliferative retinopathy, symptomatic coronary heart dis-to 1.73m2 of body surface area. The filtration fraction (FF ) ease, peripheral vascular disease or clinical autonomic neuro-was calculated as the quotient of [125I ]iothalamate and pathy as evaluated by standard tests (beat-to-beat variation [131I ]hippurate clearances. during deep breathing, Valsalva manoeuvre and systolic blood pressure response to standing). All participants were instructed by a dietician to adhere to a diet containing Analytical methods 100 mmol of sodium and 1 g of protein/kg body weight per day throughout the studies. Three timed overnight urine Blood samples were taken from an intravenous catheter at collections were obtained directly prior to the studies. the end of each clearance period with the subjects in the supine position. Blood was centrifuged immediately at 4°C and samples were stored at −20°C before assay. Aliquots of
Study design
urine for measurement of urinary proteins were stored at −20°C and analysed within 2 weeks. Plasma insulin was NE infusions were performed on three separate study days. On the first day, the NE-systemic mean arterial pressure determined by radioimmunoassay (RIA). Plasma NE was analysed by HPLC [17] . Active plasma renin was determined (MAP) dose-response curves were made. The individual NE threshold (DMAP=0 mmHg), 20% pressor (DMAP= with a commercially available double-antibody RIA (Nichols Institute Diagnostics, San Juan Capistrano, CA, USA) with 4 mmHg) and pressor (DMAP=20 mmHg) doses were calculated from NE-MAP dose-response curves. On a separate a cross-reactivity with prorenin of 0.2%. Serum ACE activity was measured with an HPLC technique. Angiotensin II was day, the stepwise NE infusions were given, with renal function measurements during 10 consecutive 45 min clearance determined by RIA (Department of Pharmacology, State University Maastricht, The Netherlands). Cross-reactivity of periods. Two baseline periods were followed by six periods of NE (two periods for threshold, 20% pressor and pressor the angiotensin II antibody with angiotensin I is <0.1%.
Serum aldosterone was determined by RIA. Blood glucose doses, respectively), after which two determinations were obtained after cessation of the infusion (recovery period ). was measured using a Yellow Springs glucose analyser (Model 23A, Yellow Springs Inc, Yellow Springs, OH, USA). Blood pressure was recorded every 5 min (DinamapA). These systemic and renal haemodynamic studies were repeated after Urinary albumin was measured with enzyme-linked immunosorbent assay (ELISA) using rabbit anti-human albumin 8 weeks of treatment with the ACE inhibitor enalapril antibody (DAKO). The detection limit is 1 mg/l. Sodium, treatment did not influence the fall in pulse rate at NE potassium, creatinine and serum albumin in serum and urine pressor dose and its rise at recovery ( Table 2 ).
were measured on SMA(C ) autoanalysers ( Technicon GFR remained essentially unaltered during NE Instruments Inc. Tarrytown, NY, USA).
infusions before and after enalapril, but declined at recovery ( Table 2) . ERPF progressively decreased at 20% pressor and at pressor dose both before and Statistical analysis during enalapril, and corresponding rises in FF were Results are expressed as mean±SEM for parametrically seen. During all observation periods, ERPF remained distributed data, and as geometric mean (95% confidence significantly higher with than before enalapril, and the intervals) for non-parametrically distributed data unless magnitude of the NE-induced decrease in ERPF was stated otherwise. The two clearance periods obtained at not influenced by enalapril treatment ( Figure 1B) . The baseline, threshold, 20% pressor, pressor and recovery were overall urinary albumin excretion rate during NE averaged for analysis. Where appropriate, repeated measure-infusion was 51.5 (24.3-109.1) mg/min before and 57.6 ments ANOVA for parametrically or non-parametrically (26.3-126.3) mg/min after enalapril (P>0.20).
distributed data were used to analyse the effects of the NE Before enalapril, plasma active renin, angiotensin II infusions before and after ACE inhibition. Paired t-tests or Wilcoxon tests were then used to establish differences between and serum aldosterone levels increased at NE pressor corresponding observation periods. Differences in NE effects dose, whereas the angiotensin II/active renin ratio on MAP and ERPF before and after ACE inhibition were remained unaltered ( Table 3) . With enalapril, plasma evaluated by comparing the overall mean changes of each active renin and serum aldosterone levels rose at NE individual. P-values <0.05 were considered to be significant. pressor dose, but plasma angiotensin II did not significantly increase. At NE pressor dose, a slight fall was seen in the angiotensin II/active renin ratio. The overall
Results
mean levels of plasma active renin, serum ACE activity, angiotensin II, the angiotensin II/active renin ratio and Metabolic control, body weight, urinary urea and serum aldosterone were lower after enalapril. sodium excretion were similar before and after
Mean blood glucose and plasma insulin concentratreatment with enalapril ( Table 1) . Enalapril lowered tions were 5.2±0.1 and 5.1±0.1 mmol/l and 230±22 baseline MAP by 5%, but did not change pulse rate and 251±19 pmol/l, before and after enalapril, respect- ( Table 2) . GFR was unaltered, whereas ERPF ively (NS ). increased by 9% ( Table 2) . FF tended to fall (P= 0.09). Overnight microalbuminuria fell by 28% ( Table 1) . Enalapril increased plasma active renin and decreased serum ACE activity and serum aldosterone levels (Table 3) . Baseline plasma angiotensin II did As expected, enalapril lowered blood pressure and overnight urinary albumin excretion, and induced renal not significantly change, but the angiotensin II/active renin ratio profoundly decreased, indicating adequate vasodilatation in microalbuminuric IDDM patients.
Discussion
The systemic haemodynamic and the renal respons-RAAS inhibition.
Plasma NE concentrations during NE infusions were iveness to exogenous NE, as well as urinary albumin excretion during NE, were, however, not altered by similar before and after ACE inhibition ( Table 2) . Before enalapril, NE increased MAP at 20% pressor ACE inhibition treatment.
Apart from general factors like basal vasomotor and pressor doses to target levels ( Table 2) . With enalapril, NE infusion also increased MAP. At NE tone and vascular reactivity, sodium and volume homeostasis as well as baroreceptor feedback control pressor dose, there was no difference in MAP compared with before enalapril. The overall mean increment in are determinants of the systemic reactivity to exogenous NE, and may thus contribute to an enhanced MAP was greater during than before enalapril (P<0.05, Figure 1A ). At recovery, MAP was again systemic NE responsiveness in diabetes mellitus [8, 11, 13, 18] . Such an exaggerated responsiveness has lower with than without enalapril. ACE inhibition Data are means±SEM and geometric mean (95% confidence intervals). *P<0.05 and **P<0.01 from corresponding infusion period without enalapril; +P<0.05 and ++P<0.01 from baseline. been found to be associated with an increased not significantly decrease exchangeable sodium in diabetes mellitus [14] . In this respect, it is noteworthy exchangeable sodium and a higher extracellular volume, and this hyper-reactivity decreases after diur-that ACE inhibition treatment induces a negative sodium balance in essential hypertension [19] . Second, etic treatment [11] . In addition, microalbuminuric IDDM patients have an attenuated pulse rate decline a similar heart rate decline during NE before and after enalapril was observed, suggesting no important alteraduring NE infusion [13] , which suggests that an altered baroreceptor feedback control may also contribute to tions in baroreceptor sensitivity, in agreement with findings in hypertensive diabetic patients [14] . Third, the systemic NE hyper-responsiveness in IDDM [18] .
The observation that enalapril treatment failed to although enalapril induced adequate RAAS suppression, it cannot be excluded that a more complete diminish systemic vascular NE reactivity in microalbuminuric IDDM is in keeping with previous findings in inhibition of angiotensin II formation is required to blunt systemic NE reactivity. Finally, we consider a diabetic patients [14, 15] . By contrast, in essential hypertension, the systemic responsiveness to NE type II error very unlikely to explain the lack of attenuation of enalapril on systemic NE reactivity, appears to be attenuated after ACE inhibition treatment [7] [8] [9] . Several factors could be involved in the since the mean increment in MAP in response to NE was even higher after ACE inhibition. lack of attenuation of the systemic NE responsiveness after ACE inhibition in diabetes mellitus. First, ACE This study is the first to document the effect of ACE inhibition treatment on NE-induced renal vasoconinhibition therapy is unlikely to have influenced sodium and volume status in the present study, since body striction in microalbuminuric IDDM patients. In IDDM, ACE inhibitors increase renal plasma flow weight remained unchanged. Indeed, captopril does a decrease in SNS activation. In the isolated kidney, ACE inhibitors indeed have been demonstrated to diminish renal vascular NE responsiveness [5, 6 ] and neuronally induced renal vasoconstriction [21] , suggesting interference in the RAAS-SNS interaction. The present in vivo study does not, however, support the assumption of an intrarenal sympathicolytic effect of enalapril in microalbuminuric IDDM patients, since the exogenous NE-induced fall in ERPF was not altered by ACE inhibition treatment.
Our findings may have clinical implications for the future design of renoprotective strategies in diabetic patients. Currently, ACE inhibition treatment is considered to be the main tool to retard the decline in renal function loss in diabetes mellitus, both by lowering systemic blood pressure and by decreasing intraglomerular pressure [1] [2] [3] . Despite this proven renoprotective potential, many patients still progress to end-stage renal failure. Despite being carried out in a small number of patients, the present study is consistent with the possibility that microalbuminuric IDDM patients are not sufficiently protected by ACE inhibition treatment against rises in systemic blood pressure due to bouts of SNS activation during daily life activities. Although the effects of exogenous NE cannot be extrapolated directly to physiological SNS stimulation, it noteworthy that increases in urinary albumin excretion are well related to rises in blood pressure and plasma NE levels during exercise, which represents a strong endogenous SNS stimulus [17] .
In conclusion, we found that enalapril does not attenuate systemic and renal vascular responsiveness to exogenous NE in microalbuminuric IDDM patients. These findings suggest that a potentially adverse effect of NE on systemic and renal vascular tone is not counteracted effectively by ACE inhibition treatment alone. 
